Rittling S R, Chambers A F
Department of Genetics, Rutgers University, Piscataway, NJ, USA.
Br J Cancer. 2004 May 17;90(10):1877-81. doi: 10.1038/sj.bjc.6601839.
Since its first identification as a transformation-associated protein, osteopontin (OPN) has been recognised as important in the processes of tumorigenicity and metastasis. Here, we review the evidence that OPN might be considered as a candidate prognostic marker in human cancer. In animal systems, evidence from cell injection experiments and genetically manipulated mice suggest an important but complex role for the protein in tumour progression. Moreover, studies in a variety of human cancers associate high levels of OPN expression in tumours or in blood with more advanced cancers. The mechanism of action of OPN in promoting cancer is still unclear, and we consider aspects of OPN biology that can complicate interpretation of human studies. Nevertheless, growing evidence supports a role for OPN as a potential prognostic factor for various human cancers.
自骨桥蛋白(OPN)首次被鉴定为一种与转化相关的蛋白以来,它在肿瘤发生和转移过程中的重要性已得到认可。在此,我们综述了相关证据,表明OPN可能被视为人类癌症的候选预后标志物。在动物实验系统中,细胞注射实验和基因操作小鼠的证据表明该蛋白在肿瘤进展中发挥着重要但复杂的作用。此外,对多种人类癌症的研究表明,肿瘤或血液中OPN的高表达与更晚期的癌症相关。OPN促进癌症的作用机制仍不清楚,我们考虑了OPN生物学的一些方面,这些方面可能会使人类研究的解释变得复杂。然而,越来越多的证据支持OPN作为各种人类癌症潜在预后因素的作用。